Controversial New Alzheimer’s Drug Approved Despite Reservations
Follow via Flickr Link: https://www.flickr.com/photos/alzmglc/15311519476/in/photolist-pk2xi7-p5zz1T-pn36eW-pk2z4G-pn4Zzt-p5yHLJ-p5yCyQ-p5yy7H-p5yKrY-p5zBtP-pn2YxE-pn4BVM-p5ztkA-pmMonT-p5ziQo-bxQfpz-pmMxTM-p5zXeR-p5zbib-p5zQFk-pn3m45-pk2Tsf-p5zB8E-pn4N6g-4eGjGS-CFX1-pk2JQf-WfWjgu-pk2Lc3-3hQn2G-4kkzZx-6DojR2-51m44-7rJbFK-9YAmBr-fkWSC9-44Aksc-nSqng6-GAH7BD-j1M1Sk-gv1YhP-6Doi7x-3xK9k-6DoitF-dwaKm8-fkWSGw-6DoiYK-6DssxN-MhcFWN-o17RFw
The U.S. Food and Drug Administration has approved the first new drug for Alzheimer’s disease in 20 years, but some doctors, including one at UAB, warned patients’ families not to expect much from the drug any time soon.
The drug, aducanumab, is expected to help slow the progression of the disease, but not to improve current memory impairments, according to a release from the University of Alabama at Birmingham. The university’s Division of Memory Disorders and the Alzheimer’s Disease Center have been involved in clinical trials of aducanumab for the past five years.
“The approval of the first disease-modifying therapy is a milestone for our field and a result of years of intense research. However, it must be understood that [aducanumab] is not expected to restore memory or reverse the symptoms of Alzheimer’s disease,” said Dr. David Geldmacher, professor of neurology at UAB and clinical core director of the center. “Instead, it is expected to slow the worsening of the disease. [Aducanumab] is likely the beginning of a new era in treating AD, but not the end of the story.”
Geldmacher said it would be some time before the drug is widely available, not all patients will be eligible to receive it, and many patients, especially with advanced disease, are not likely to see improvement from it.
The FDA approved the drug despite opposition from an independent advisory committee and some Alzheimer’s experts who said there was not enough evidence the drug helps patients, according to several news reports, including from the Associated Press.
The FDA did require the drugmaker, Biogen, to conduct another study to determine whether it benefits patients, and it could pull the drug from the market if its effectiveness is not proven.
Editor’s Note: UAB holds WBHM’s broadcast license, but our news and business departments operate independently.
Americans’ medical debt can stay in credit reports, judge rules. What does that mean?
The judge's decision vacated a rule imposed by the Biden administration earlier this year to keep medical debt from affecting credit scores.
Attorney General Bondi brushes aside questions about her handling of Epstein files
Pam Bondi sought to move past questions about her handling of the Justice Department's files from the Jeffrey Epstein investigation, as pressure continued to grow for her to release them.
Increase in military aid to Ukraine marks a shift in White House policy toward Russia
The Pentagon and U.S. military officials in Europe are working with NATO members to ship more Patriot missile systems to Ukraine and release more munitions that were briefly halted.
Texas flash flood recovery effort turns its focus to lakes
With 101 people still missing after the July 4 flash flood, the focus turns to local lakes, and what may be buried in them.
U.S. senator wants DOGE out of sensitive payment system for farmers
Sen. Tammy Baldwin, D-Wis., wants the USDA to revoke high-level access granted to the Department of Government Efficiency to a database that controls payments and loans to farmers and ranchers.
Lawyer says an Alabama teen who was killed by police was shot in the back
Authorities have not released police body camera video of the June 23 encounter or disclosed the name of the officer who shot 18-year-old Jabari Peoples in the parking lot of a soccer field in the affluent Birmingham suburb of Homewood. They also haven't released the findings of the county's official autopsy.
